Cargando…
Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
Treatment of relapsed/refractory diffuse large B‐cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR‐T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET‐derived parameters, the report of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086831/ https://www.ncbi.nlm.nih.gov/pubmed/36120952 http://dx.doi.org/10.1111/bjh.18468 |